We seek to transform the standard of care
in hypertrophic cardiomyopathy
and related conditions.
Mission and vision statement
Our mission is to advance a novel cardiac myosin inhibitor that can improve the treatment of [obstructive] hypertrophic cardiomyopathy by reducing patients’ symptoms rapidly and preserving patients’ ability to live active lives.
Our Science
Our Approach
Feature one
Our Approach
Our approach is rooted in a deep understanding of HCM. We leverage advanced research and clinical development to bring forward a novel cardiac myosin inhibitor with the potential to significantly improve patient outcomes and enhance their quality
of life.
Our Lead Asset
Feature two
Our Lead Asset
Our lead asset, BH-1893, was engineered for properties that may offer practical advantages to current therapies. In data to date, BH-1893 has demonstrated it can reduce the blockage in the heart, leading to improved blood flow and reduced symptom; is generally well-tolerated with manageable side effects; and begins working quickly, with some patients experiencing improvement within weeks. These characteristics, if confirmed in late-stage trials, could make treatment more accessible and convenient for patients.
Pipeline
Feature three
Pipeline
We believe our molecule has best-in-class potential, and with that, the potential to transform the standard of care and help meet the unmet needs of a range of patients – from youth to middle age – impacted by obstructive hypertrophic cardiomyopathy (oHCM)
Ready to join?
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt. Consectetur adipiscing elit, sed do eiusmod tempor incididunt.